Emerging treatment options for uterine fibroids

被引:35
作者
Donnez, Jacques [1 ]
Arriagada, Pablo [2 ]
Donnez, Olivier [3 ]
Dolmans, Marie-Madeleine [4 ,5 ]
机构
[1] Catholic Univ Louvain, SRI, Brussels, Belgium
[2] Gedeon Richter Preglem SA, Geneva, Switzerland
[3] Polyclin Urbain V, ELSAN Grp, Inst Sein & Chirurg Gynecol Avignon, Avignon, France
[4] Clin Univ St Luc, Gynecol Dept, Brussels, Belgium
[5] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Gynecol, Brussels, Belgium
关键词
Uterine fibroids; leiomyomas; selective progesterone receptor modulators; ulipristal acetate; surgery; medical therapy; myomectomy; infertility; PROGESTERONE-RECEPTOR MODULATORS; ULIPRISTAL ACETATE; MANAGEMENT;
D O I
10.1080/14728214.2018.1446943
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate. We searched all published studies on medical management of fibroids with SPRMs. Expert opinion: The need for alternatives to surgical intervention is very real, especially for women seeking to preserve their fertility. These options now exist, with SPRMs proven to treat fibroid symptoms effectively. Gynecologists now have new tools in their armamentarium, opening up novel strategies for the management of uterine fibroids.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 22 条
[1]   The potential of selective progesterone receptor modulators for the treatment of uterine fibroids [J].
Bestel, Elke ;
Donnez, Jacques .
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (01) :79-92
[2]   Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety [J].
Bouchard, Philippe ;
Chabbert-Buffet, Nathalie ;
Fauser, Bart C. J. M. .
FERTILITY AND STERILITY, 2011, 96 (05) :1175-1189
[3]   Fibroid growth and medical options for treatment [J].
Chabbert-Buffet, Nathalie ;
Esber, Nathalie ;
Bouchard, Philippe .
FERTILITY AND STERILITY, 2014, 102 (03) :630-639
[4]  
Courtoy G, 2018, REPROD BIOMED ONLINE
[5]  
Courtoy G. E., 2018, J CLIN ENDOCRINOL ME
[6]   In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment [J].
Courtoy, Guillaume E. ;
Donnez, Jacques ;
Marbaix, Etienne ;
Dolmans, Marie-Madeleine .
FERTILITY AND STERILITY, 2015, 104 (02) :426-+
[7]   Uterine fibroid management: from the present to the future [J].
Donnez, Jacques ;
Dolmans, Marie-Madeleine .
HUMAN REPRODUCTION UPDATE, 2016, 22 (06) :665-686
[8]   Long-term medical management of uterine fibroids with ulipristal acetate [J].
Donnez, Jacques ;
Donnez, Olivier ;
Matule, Dace ;
Ahrendt, Hans-Joachim ;
Hudecek, Robert ;
Zatik, Janos ;
Kasilovskiene, Zaneta ;
Dumitrascu, Mihai Cristian ;
Fernandez, Herve ;
Barlow, David H. ;
Bouchard, Philippe ;
Fauser, Bart C. J. M. ;
Bestel, Elke ;
Loumaye, Ernest .
FERTILITY AND STERILITY, 2016, 105 (01) :165-+
[9]   Long-term treatment of uterine fibroids with ulipristal acetate [J].
Donnez, Jacques ;
Vazquez, Francisco ;
Tomaszewski, Janusz ;
Nouri, Kazem ;
Bouchard, Philippe ;
Fauser, Bart C. J. M. ;
Barlow, David H. ;
Palacios, Santiago ;
Donnez, Olivier ;
Bestel, Elke ;
Osterloh, Ian ;
Loumaye, Ernest .
FERTILITY AND STERILITY, 2014, 101 (06) :1565-U405
[10]   Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids [J].
Donnez, Jacques ;
Tomaszewski, Janusz ;
Vazquez, Francisco ;
Bouchard, Philippe ;
Lemieszczuk, Boguslav ;
Baro, Francesco ;
Nouri, Kazem ;
Selvaggi, Luigi ;
Sodowski, Krzysztof ;
Bestel, Elke ;
Terrill, Paul ;
Osterloh, Ian ;
Loumaye, Ernest .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (05) :421-432